A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products

European Journal of Pharmaceutical Sciences

Volumn 30, Issue 1, 2007, Pages 15-20

  Schellekens, R C A ^a,b   Stuurman, F E ^b   van der Weert, F H J ^a   Kosterink, J G W ^a   Frijlink, H W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

5 Aminosalicylic acid; Biorelevant media; Colon; Dissolution; Drug release; Mesalazine; Simulation

Indexed keywords

MESALAZINE;

ARTICLE; COLON; CONTROLLED DRUG RELEASE; DOSE TIME EFFECT RELATION; DRUG DOSAGE FORM COMPARISON; DRUG GRANULE; DRUG RELEASE; DRUG SOLUBILITY; EVALUATION; GASTROINTESTINAL SIMULATION SYSTEM; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; OSMOLALITY; PRIORITY JOURNAL; SIMULATION; STOMACH PH; TABLET;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; INTESTINES; MESALAMINE; MODELS, BIOLOGICAL; SOLUBILITY; STOMACH;

EID: 33845415573     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.09.004     Document Type: Article

References (31)

1. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Azad Khan A.K., Piris J., and Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2 (1977) 892-895
3. Barrow L., Steed K.P., Spiller R.C., Watts P.J., Melia C.D., Davies M.C., and Wilson C.G. Scintigraphic demonstration of lactulose-induced accelerated proximal colon transit. Gastroenenterology 103 (1992) 1167-1173
4. 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol. Ther. 17 (2003) 1163-1169
5. Coupe A.J., Davis S.S., and Wilding I.R. Variation in gastrointestinal transit in pharmaceutical dosage forms. Pharm. Res. 3 (1991) 360-364
6. Cummings J.H., Pomare E.W., Branch W.J., Naylor C.P.E., and MacFarlane G.T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28 (1987) 1221-1227
7. Davis S.S., Hardy J.G., and Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 27 (1986) 886-892
8. Davis S.S., Hardy J.G., Taylor M.J., Whalley D.R., and Wilson C.G. A comparative study of the gastrointestinal transit of a pellet and a tablet formulation. Int. J. Pharm. 21 (1984) 167-177
9. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 (1998) 11-22
10. Evans D.F., Pye G., Bramley R., Clark A.G., Dyson T.J., and Hardcastle J.D. Measurement of gastrointestinal pH profiles in normal ambulant subjects. Gut 29 (1988) 1035-1041
11. Ewe K., Schwartz S., Petersen S., and Press A.G. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig. Dis. Sci. 44 7 (1999) 1434-1439
12. Frijlink H.W. β-Cyclodextrin as an excipient in solid oral dosage forms. In vitro and in vivo evaluation of spray-dried diazepam-β-cyclodextrin products. In: Frijlink H.W. (Ed). Biopharmaceutical Aspects of Cyclodextrins (1990) 101-116
13. Gorissen, H.R.M., Frijlink, H.W., Verhage, M., 2001. Ionic strength independent sustained release pharmaceutical formulation, Int. Patent PCT/EP01/11285.
14. Haagen N.O., and Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br. J. Clin. Pharmacol. 16 6 (1983) 738-740
15. ® S-100 coated pellets. Pharm. Res. 12 (1995) 1813-1816
16. Katori N., Aoyagi N., and Terao T. Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation. Pharam. Res. 12 (1995) 237-243
17. Klein, S., Rudolph, M.W., Dressman, J.B., 2002. Drug release characteristics of different mesalazine products using USP Apparatus 3 to simulate passage through the GI tract. Dis. Tech.
18. Klein S., Stein J., and Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model. J. Pharm. Pharmacol. 57 6 (2005) 709-719
19. Klotz U., Maier K.E., Fisher C., and Bauer K.H. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Drug Res. 35 I (1985) 636-639
20. Klotz U. Clinical pharmacokinetics of sulphasalazine and 5-ASA. Clin. Pharmacokin. 10 (1985) 285-302
21. Lewis J.D. How safe are the safest IBD drugs?. Gastroenterology 124 (2003) 1986-1995
22. Meese C.O., Fisher C., and Klotz U. Is N-acetylation of 5-aminosalicylic acid reversible in man?. Br. J. Clin. Pharm. 18 (1984) 612-615
23. Myers B., Evans D.N., Rhodes J., Evans B.K., Hughes B.R., Lee M.G., Richens A., and Richards D. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 28 (1987) 196-200
24. Press A.G., Hauptmann I.A., Hauptmann L., Fuchs B., Fuchs M., Ewe K., and Ramadori G. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol. Ther. 12 (1998) 673-678
25. Qureshi A.I., and Cohen R.D. Mesalamine delivery systems: do they really make much difference?. Adv. Drug Delivery Rev. 57 (2005) 281-302
26. Sasaki Y., Hada R., Nakajima H., Fukuda S., and Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease. Am. J. Gastroenterol. 92 (1997) 114-118
27. Steed K.P., Hooper G., Monti N., Strolin Benedetti M., Fornasini G., and Wilding I.R. The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system. J. Control. Release 49 (1997) 115-122
28. Stolk L.M., Rietbroek R., Wiltink E.H., and Tukker J.J. Dissolution profiles of mesalazine formulations in vitro. Pharm. Weekbl. Sci. 12 5 (1990) 200-204
29. Sutherland L., Roth D., Beck P., May G., and Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (Cochrane review). The Cochrane Library, no. 1 (2004), John Wiley & Sons, Ltd., Chichester, UK
30. Vree T.B., Dammers E., Exler P.S., and Maes R.A. Multiple absorption patterns of mesalazine from two gastroresistant tablets in healthy male volunteers. Clin. Drug Invest. 21 (2001) 295-305
31. Zhou S.Y., Fleisher D., Pao L.H., Li C., Winward B., and Zimmermann E.M. Intestinal metabolism and transport of 5-aminosalicaylate. Drug Metab. Dispos. 27 (1999) 479-485